These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 31092729)

  • 1. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
    Jia Q; Wang J; He N; He J; Zhu B
    JCI Insight; 2019 May; 4(10):. PubMed ID: 31092729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
    Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
    Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
    Pan D; Hu AY; Antonia SJ; Li CY
    J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
    Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
    Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
    DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; Rumilla KM; Voss JS; Seetharam M; Sekulic A; Markovic SN; Bryce AH
    PLoS One; 2020; 15(3):e0230306. PubMed ID: 32196516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.